| | Variable | All guideline concordant care | Radiation following Lumpectomy | Radiation following Mastectomy | Chemotherapy for ER-positive Disease1 | Chemotherapy for ER-negative Disease2 |
| | N | 5,247 | 4,085 | 321 | 1,453 | 816 |
| | Concordant | | | | | | | Yes | 4,168 (79.4%) | 3,736 (91.5%) | 285 (88.8%) | 929 (63.9%) | 578 (70.8%) | | No | 1,079 (20.6%) | 349 (8.5%) | 36 (11.2%) | 524 (36.1%) | 238 (29.2%) |
| | Imaging | | | | | | | Mammogram/US | 3,525 (67.2%) | 2,888 (70.7%) | 148 (46.1%) | 858 (59.1%) | 542 (66.4%) | | Breast MRI | 1,190 (22.7%) | 921 (22.5%) | 82 (25.5%) | 350 (24.1%) | 145 (17.8%) | | PET/CT | 532 (10.1%) | 276 (6.8%) | 91 (28.3%) | 245 (16.9%) | 129 (15.8%) |
| | Age3 (mean years ± standard deviation, range) | 66.1 ± 12.7
(26–103) | 66.4 ± 12.2
(26–103) | 64.5 ± 13.9
(32–92) | 64.3 ± 13.0
(30–93) | 64.2 ± 13.8 (26–96) |
| | Race (White non-Hispanic) | | | | | | | Yes | 4,804 (91.6%) | 3,773 (92.4%) | 284 (88.5%) | 1,328 (91.4%) | 718 (88.0%) | | No | 443 (8.4%) | 312 (7.6%) | 37 (11.5%) | 125 (8.6%) | 98 (12%) |
| | Rural/urban residence | | | | | | | Urban | 4,672 (89.0%) | 3,632 (88.9%) | 291 (90.7%) | 1,295 (89.1%) | 714 (87.5%) | | Large | 360 (6.9%) | 283 (6.9%) | 18 (5.6%) | 104 (7.2%) | 61 (7.5%) | | Small | 215 (4.1%) | 170 (2.4%) | 12 (3.7%) | 54 (3.7%) | 41 (5.0%) |
| | Health insurer type | | | | | | | Medicare | 2,498 (47.6%) | 1,981 (48.5%) | 133 (41.4%) | 661 (45.5%) | 339 (41.5%) | | Fee for service | 1,059 (20.2%) | 822 (20.1%) | 61 (19.0%) | 307 (21.0%) | 177 (21.7%) | | Managed care | 1,334 (25.4%) | 1,027 (25.1%) | 97 (30.2%) | 370 (25.5%) | 233 (28.6%) | | Medicaid | 189 (3.6%) | 125 (3.1%) | 18 (5.6%) | 72 (5.0%) | 42 (5.1%) | | Multiple | 167 (3.2%) | 130 (3.2%) | 12 (3.7%) | 43 (3.0%) | 25 (3.1%) |
| | Log of median income (mean ± standard deviation, range) | 10.8 ± 0.3
(9.3–11.8 ) | 10.8 ± 0.3
(9.3–11.8) | 10.8 ± 0.3
(9.6–11.8) | 10.8 ± 0.3
(9.3–11.8) | 10.8 ± 0.3
(9.3–11.8) |
| | Year of diagnosis | | | | | | | 2002 | 622 (11.9%) | 491 (12.0%) | 40 (12.5%) | 174 (12.0%) | 87 (10.7%) | | 2003 | 663 (12.6%) | 502 (12.3%) | 43 (13.4%) | 177 (12.2%) | 113 (13.8%) | | 2004 | 673 (12.8%) | 518 (12.7%) | 46 (14.3%) | 196 (13.5%) | 114 (14.0%) | | 2005 | 832 (15.9%) | 642 (15.7%) | 51 (15.9%) | 235 (16.2%) | 129 (15.8%) | | 2006 | 836 (15.9%) | 672 (16.5%) | 45 (14.0%) | 209 (14.4%) | 128 (15.7%) | | 2007 | 834 (15.9%) | 641 (15.7%) | 58 (18.1%) | 248 (17.1%) | 126 (15.4%) | | 2008 | 787 (15.0%) | 619 (15.2%) | 38 (11.8%) | 214 (14.7%) | 119 (14.6%) |
| | Comorbidity4 (mean ± standard deviation, range) | 0.2 ± 0.4
(0–3.4) | 0.1 ± 0.4
(0–3.4) | 0.2 ± 0.4
(0–2.5) | 0.2 ± 0.4
(0–3.3) | 0.2 ± 0.4
(0–3.1) |
| | Time from diagnosis to definitive surgery (days) | | | | | | | ≤60 | 4,683 (89.3%) | 3,665 (89.7%) | 286 (89.1%) | 1,280 (88.1%) | 740 (90.7%) | | >60 | 564 (10.7%) | 420 (10.3%) | 35 (10.9%) | 173 (11.9%) | 76 (9.3%) |
|
|
